Fenofibrate or Gemfibrozil for Treatment of Types IIa and IIb Primary Hyperlipoproteinemia: A Randomized, Double-Blind, Crossover Study
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in Endocrine Practice
- Vol. 8 (2) , 96-101
- https://doi.org/10.4158/ep.8.2.96
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999
- Factors involved in the maintenance of endothelial functionThe American Journal of Cardiology, 1998
- Low-density lipoproteins and risk for coronary artery diseaseThe American Journal of Cardiology, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Cholesterol Reduction Yields Clinical BenefitCirculation, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type Ha or IIb HyperlipidemiaArchives of internal medicine (1960), 1994
- Once-daily, extended-release gemfibrozil in patients with dyslipidemiaThe American Journal of Cardiology, 1993
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987